Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Completed Phase 2 Interventional

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

NCT07102459
View directory record Official record
Conditions
Acute Pain, Postoperative Pain Control
Interventions
Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP, Placebo Comparator
Drug
Lead sponsor
Latigo Biotherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Atlanta, Georgia • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

NCT03439670
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone, Prednisone, Placebo
Drug · Other
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Davis, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 22, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

NCT03091439
View directory record Official record
Conditions
Osteomyelitis
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 22, 2026, 6:53 AM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 22, 2026, 6:53 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children

NCT07861321
View directory record Official record
Conditions
Dental Caries
Interventions
Nano Silver Fluoride / NSF
Device
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
6 Years to 10 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients

NCT06409819
View directory record Official record
Conditions
Urinary Tract Infection, Recurrent
Interventions
phage therapy, control
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 22, 2026, 6:53 AM EDT
Terminated Phase 4 Interventional Results available

Thiazolidinedione Intervention With Vitamin D Evaluation

NCT00879970
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo
Drug · Dietary Supplement
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
1,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 22, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

PR3-AAV Resilient Remission or PRRR

NCT05376319
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
Interventions
Obinutuzumab, Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy

NCT00550290
View directory record Official record
Conditions
Wound Infection
Interventions
Cefazolin PostOperatively, Cefazolin Preoperatively
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 1 Interventional

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT03639246
View directory record Official record
Conditions
Ovarian Cancer
Interventions
AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD), Placebo
Drug · Other
Lead sponsor
Aravive, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 22, 2026, 6:53 AM EDT
Withdrawn Phase 3 Interventional

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Withdrawn Phase 2 Interventional

Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury

NCT02443142
View directory record Official record
Conditions
Brain Concussion
Interventions
Ibuprofen, Acetaminophen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

NCT06579105
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Mobile, Alabama • Sheffield, Alabama • Vestavia Hills, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

NCT00308308
View directory record Official record
Conditions
Diabetes, Type I
Interventions
Technosphere Insulin, Active comparator
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 22, 2026, 6:53 AM EDT
Recruiting Phase 3 Interventional

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

NCT04510597
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cytoreductive Nephrectomy, Active Comparator
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
387
States / cities
Birmingham, Alabama • Gilbert, Arizona • Kingman, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

NCT05464420
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
2,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
30
States / cities
Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Synaquell™ in Contact Sport Athletes

NCT06104670
View directory record Official record
Conditions
Healthy
Interventions
Synaquell(TM), Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of the SafeSpace App Intervention

NCT06043596
View directory record Official record
Conditions
Health Behavior, Health Care Utilization, Unprotected Sex, Sexually Transmitted Infections
Interventions
SafeSpace Sexual Health, SafeSpace General Health
Behavioral
Lead sponsor
Child Trends
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.

NCT00417261
View directory record Official record
Conditions
Healthy
Interventions
ATF936, AXT914
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 68 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2008 · Synced Oct 22, 2026, 6:53 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of a Black Rice Extract and Anthocyanidin Metabolites on the Synthesis and Release of BDNF in Healthy Subjects

NCT06594848
View directory record Official record
Conditions
Cognition - Other, Depression, Anxiety
Interventions
Black rice extract, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 6:53 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities)

NCT02986126
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Resiliency Class, Resource for Services (RS)
Behavioral · Other
Lead sponsor
Bowen Chung, MD, MSHS
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
22
States / cities
Compton, California • Long Beach, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 22, 2026, 6:53 AM EDT
Completed Phase 2 Interventional

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 22, 2026, 6:53 AM EDT